EVS Glaucoma Therapeutics
Herndon, Virginia
CEO: Michael A. Ross
Company Status: Active
Investment Status: Current
Fund: GAP BioLife Fund
Developer of a bio-absorbable, humanized collagen implant capable of sustained delivery of Latanoprost, the #1 prescribed glaucoma medication.